Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature

PARP inhibitors are progressively becoming a part of our therapeutic arsenal against BRCA-defective tumors, because of their capacity to induce synthetic lethality in cells with a deficiency in the homologous recombination repair system. Olaparib and talazoparib have been approved for metastatic bre...

Full description

Bibliographic Details

Published in:	Frontiers in oncology Vol. 13; p. 1158981
Main Authors:	Albarrán, Víctor, Chamorro, Jesús, Pozas, Javier, San Román, María, Rosero, Diana Isabel, Saavedra, Cristina, Gion, María, Cortés, Alfonso, Escalera, Elena, Guerra, Eva, López Miranda, Elena, Fernández Abad, María, Martínez Jañez, Noelia
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 05-05-2023
Subjects:	BRCA breast cancer germline olaparib Oncology PARP inhibitors talazoparib BRCA breast cancer germline talazoparib PARP inhibitors olaparib
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!